AUTL · NASDAQ
Autolus Therapeutics (AUTL) Stock Price & Fundamentals
Autolus Therapeutics (AUTL) closed at $273.79 on Oct 9, 2026, down 1.18% from the previous close of $277.05.
Share price, past year
1Y −7.52%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $273.79 |
| Sep 30, 2026 | $276.99 |
| Aug 31, 2026 | $278.87 |
| Jul 31, 2026 | $274.40 |
| Jun 30, 2026 | $280.94 |
| May 29, 2026 | $279.08 |
| Apr 30, 2026 | $280.82 |
| Mar 31, 2026 | $285.66 |
| Feb 27, 2026 | $303.50 |
| Jan 30, 2026 | $305.89 |
| Dec 31, 2025 | $301.09 |
| Nov 28, 2025 | $305.93 |
| Oct 31, 2025 | $299.00 |
Key statistics
- Market cap
- $72.87B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.06
- Revenue (TTM)
- $117.39M
- Net income (TTM)
- −$280.16M
- Shares outstanding
- 266.2M
- Dividend yield
- —
- 52-week range
- $263.80 – $316.25
Autolus Therapeutics's market cap is $72.87B, based on a share price of $273.79 and 266.2M shares outstanding as of Aug 10, 2026.
Financials
Autolus Therapeutics reported revenue of $75.39M for fiscal 2025, up 644.94% from fiscal 2024.
Autolus Therapeutics reported a net loss of $287.53M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 7 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $75.39M | +644.9% | −$287.53M | −381.4% | −$1.08 | −$302.61M |
| FY2024ended Dec 31, 2024 | $10.12M | +496.0% | −$220.66M | −2,180.5% | −$0.86 | −$228.35M |
| FY2023ended Dec 31, 2023 | $1.70M | −41.6% | −$208.38M | −12,272.3% | −$1.20 | −$156.57M |
| FY2019ended Dec 31, 2019 | $2.91M | +106.7% | −$123.85M | −4,258.9% | −$2.88 | −$119.83M |
| FY2018ended Sep 30, 2018 | $1.41M | −16.9% | −$44.75M | −3,180.6% | −$1.42 | −$40.66M |
| FY2017ended Sep 30, 2017 | $1.69M | +39.7% | −$19.73M | −1,165.2% | −$1.43 | −$19.24M |
| FY2016ended Sep 30, 2016 | $1.21M | — | −$12.55M | −1,035.5% | −$1.26 | −$11.70M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $45.69M | −$39.11M | −$0.15 |
| Q1 FY2026ended Mar 31, 2026 | $26.22M | −$71.60M | −$0.27 |
| Q4 FY2025ended Dec 31, 2025 | $24.29M | −$90.33M | −$0.34 |
| Q3 FY2025ended Sep 30, 2025 | $21.19M | −$79.12M | −$0.30 |
| Q2 FY2025ended Jun 30, 2025 | $20.92M | −$47.92M | −$0.18 |
| Q1 FY2025ended Mar 31, 2025 | $8.98M | −$70.16M | −$0.26 |
| Q4 FY2024ended Dec 31, 2024 | $29.00K | −$27.61M | −$0.09 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$82.09M | −$0.31 |
Company profile
- Name
- Autolus Therapeutics plc
- Ticker
- AUTL
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- The Mediaworks, 191 Wood Lane, London, X0 W12 7FP
- Incorporated in
- X0
- Fiscal year ends
- December
- SEC CIK
- 0001730463
Recent SEC filings
- Aug 11, 2026
- Aug 11, 2026
- Aug 3, 2026
- Aug 3, 2026
- Jun 29, 2026
- Jun 9, 2026
- May 14, 2026
- May 14, 2026
Frequently asked questions
What is Autolus Therapeutics's stock price?
Autolus Therapeutics (AUTL) closed at $273.79 on Oct 9, 2026, down 1.18% from the previous close of $277.05.
What is Autolus Therapeutics's market cap?
Autolus Therapeutics's market cap is $72.87B, based on a share price of $273.79 and 266.2M shares outstanding as of Aug 10, 2026.
How much revenue does Autolus Therapeutics make?
Autolus Therapeutics reported revenue of $75.39M for fiscal 2025, up 644.94% from fiscal 2024.
Does Autolus Therapeutics pay a dividend?
Autolus Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Autolus Therapeutics plc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures